Genes Expressed in Human Tumor Endothelium
10.1126/science.289.5482.1197
Crossref journal-article
American Association for the Advancement of Science (AAAS)
Science (221)
Abstract

To gain a molecular understanding of tumor angiogenesis, we compared gene expression patterns of endothelial cells derived from blood vessels of normal and malignant colorectal tissues. Of over 170 transcripts predominantly expressed in the endothelium, 79 were differentially expressed, including 46 that were specifically elevated in tumor-associated endothelium. Several of these genes encode extracellular matrix proteins, but most are of unknown function. Most of these tumor endothelial markers were expressed in a wide range of tumor types, as well as in normal vessels associated with wound healing and corpus luteum formation. These studies demonstrate that tumor and normal endothelium are distinct at the molecular level, a finding that may have significant implications for the development of anti-angiogenic therapies.

Bibliography

Croix, B. St., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., & Kinzler, K. W. (2000). Genes Expressed in Human Tumor Endothelium. Science, 289(5482), 1197–1202.

Authors 11
  1. Brad St. Croix (first)
  2. Carlo Rago (additional)
  3. Victor Velculescu (additional)
  4. Giovanni Traverso (additional)
  5. Katharine E. Romans (additional)
  6. Elizabeth Montgomery (additional)
  7. Anita Lal (additional)
  8. Gregory J. Riggins (additional)
  9. Christoph Lengauer (additional)
  10. Bert Vogelstein (additional)
  11. Kenneth W. Kinzler (additional)
References 43 Referenced 1,487
  1. 10.1056/NEJM197108122850711
  2. ___ in Cancer Medicine J. Holland et al. Eds. (Williams & Wilkins Baltimore 1997) pp. 181–204.
  3. Kerbel R. S., Carcinogenesis 21, 505 (2000). (10.1093/carcin/21.3.505) / Carcinogenesis by Kerbel R. S. (2000)
  4. For example see www.sagenet.org/angio/vwf.htm.
  5. Q. G. Dong et al. Arterioscler. Thromb. Vasc. Biol. 17 1599 (1997).
  6. Hewett P. W., Murray J. C., In Vitro Cell. Dev. Biol. Anim. 32, 462 (1996). (10.1007/BF02723047) / In Vitro Cell. Dev. Biol. Anim. by Hewett P. W. (1996)
  7. Hull M. A., Hewett P. W., Brough J. L., Hawkey C. J., Gastroenterology 111, 1230 (1996). (10.1053/gast.1996.v111.pm8898637) / Gastroenterology by Hull M. A. (1996)
  8. G. Haraldsen et al. Gut 37 225 (1995). (10.1136/gut.37.2.225)
  9. The original EC isolation protocol was the same as that described in Fig. 1B except that dispersed cells were stained with antibody to CD31 (anti-CD31) instead of anti-P1H12 and magnetic beads against CD64 and CD14 were not included in the negative selection. Analysis of 120 000 SAGE tags from these two EC preparations revealed high levels of more than 15 selected markers predominantly expressed on macrophages.
  10. A. Solovey et al. N. Engl. J. Med. 337 1584 (1997). (10.1056/NEJM199711273372203)
  11. Several modifications to the original SAGE protocol have reduced the amount of starting material required (36 37). A detailed version of our modified “MicroSAGE” protocol is available at www.sagenet.org/sage_protocol.htm.
  12. 10.1126/science.270.5235.484
  13. We analyzed 96 694 and 96 588 SAGE tags from normal and tumor-derived ECs respectively of which 50 298 tags were unique. We derived a conservative estimate of 32 703 unique transcripts by considering only those tags observed more than once in the current data set or in the 134 000 transcripts previously identified in human transcriptomes (38).
  14. To identify pan endothelial-specific transcripts we normalized the number of tags analyzed in each group to 100 000 and limited our analysis to transcripts that were expressed at levels at least 20-fold higher in ECs than in nonendothelial cell lines in culture and present at fewer than five copies per 100 000 transcripts in nonendothelial cell lines and the hematopoietic fraction (∼57 000 tags) (39). Nonendothelial cell lines consisted of 1.8 × 10 6 tags derived from a total of 14 different cancer cell lines including colon breast lung and pancreatic cancers as well as one nontransformed keratinocyte cell line two kidney epithelial cell lines and normal monocytes. A complete list of PEMs is available at www.sagenet.org/angio/table1.htm.
  15. M. Tucci et al. J. Endocrinol. 157 13 (1998). (10.1677/joe.0.1570013)
  16. T. Oono et al. J. Invest. Dermatol. 100 329 (1993).
  17. Jendraschak E., Sage E. H., Semin. Cancer Biol. 7, 139 (1996). (10.1006/scbi.1996.0019) / Semin. Cancer Biol. by Jendraschak E. (1996)
  18. N. Bardin et al. Tissue Antigens 48 531 (1996). (10.1111/j.1399-0039.1996.tb02666.x)
  19. Bradham D. M., Igarashi A., Potter R. L., Grotendorst G. R., J. Cell Biol. 114, 1285 (1991). (10.1083/jcb.114.6.1285) / J. Cell Biol. by Bradham D. M. (1991)
  20. K. Akaogi et al. Proc. Natl. Acad. Sci. U.S.A. 93 8384 (1996). (10.1073/pnas.93.16.8384)
  21. Y. Muragaki et al. Proc. Natl. Acad. Sci. U.S.A. 92 8763 (1995). (10.1073/pnas.92.19.8763)
  22. Iruela-Arispe M. L., Diglio C. A., Sage E. H., Arterioscler. Thromb. 11, 805 (1991). (10.1161/01.ATV.11.4.805) / Arterioscler. Thromb. by Iruela-Arispe M. L. (1991)
  23. Girard J. P., Springer T. A., Immunity 2, 113 (1995). (10.1016/1074-7613(95)90083-7) / Immunity by Girard J. P. (1995)
  24. E. A. Jaffe et al. J. Immunol. 143 3961 (1989). (10.4049/jimmunol.143.12.3961)
  25. J. P. Girard et al. Am. J. Pathol. 155 2043 (1999). (10.1016/S0002-9440(10)65523-X)
  26. Ohtani H., Sasano N., J. Electron Microsc. 36, 204 (1987). / J. Electron Microsc. by Ohtani H. (1987)
  27. For nonradioactive in situ hybridization digoxigenin (DIG)-labeled antisense RNA probes were generated by PCR amplification of 500- to 600-bp products and incorporation of a T7 promoter into the antisense primer. In vitro transcription was performed with DIG RNA labeling reagents and T7 RNA polymerase (Roche Indianapolis IN). Frozen tissue sections were fixed with 4% paraformaldehyde permeabilized with pepsin and incubated with RNA probe (200 ng/ml) overnight at 55°C. For signal amplification a horseradish peroxidase (HRP) rabbit anti-DIG antibody (DAKO Carpinteria CA) was used to catalyze the deposition of Biotin-Tyramide (GenPoint kit DAKO). Further amplification was achieved by adding HRP rabbit anti-biotin (DAKO) biotin-tyramide and then alkaline-phosphatase (AP) rabbit anti-biotin (DAKO). Signal was detected with the AP substrate Fast Red TR/Napthol AS-MX (Sigma St. Louis MO) and cells were counterstained with hematoxylin unless otherwise indicated. A detailed protocol including the list of primers used to generate the probes can be obtained from the authors upon request.
  28. Differentially expressed endothelial-specific transcripts were defined as those expressed at levels at least fivefold higher in ECs in vivo than in nonendothelial cell lines in culture (14) and present at no more than five copies per 100 000 transcripts in nonendothelial cell lines and the hematopoietic cell fraction (39). Transcripts showing statistically different levels of expression ( P < 0.05) were then identified by Monte Carlo analysis (40). Transcripts preferentially expressed in normal endothelium were then defined as those expressed at levels at least 10-fold higher in normal endothelium than in tumor endothelium. Conversely tumor endothelial transcripts were present at levels at least 10-fold higher in tumor versus normal endothelium. See www.sagenet.org/angio/table2.htm and www.sagenet.org/angio/table3.htm for a complete list of differentially expressed genes.
  29. M. Iurlaro et al. Eur. J. Clin. Invest. 29 793 (1999). (10.1046/j.1365-2362.1999.00532.x)
  30. W. S. Lee et al. Circ. Res. 82 845 (1998). (10.1007/s11606-998-0017-2)
  31. Niquet J., Represa A., Brain. Res. Dev. Brain Res. 95, 227 (1996). (10.1016/0165-3806(96)00089-2) / Brain. Res. Dev. Brain Res. by Niquet J. (1996)
  32. Fouser L., Iruela-Arispe L., Bornstein P., Sage E. H., J. Biol. Chem. 266, 18345 (1991). (10.1016/S0021-9258(18)55276-5) / J. Biol. Chem. by Fouser L. (1991)
  33. Iruela-Arispe M. L., Hasselaar P., Sage H., Lab Invest. 64, 174 (1991). / Lab Invest. by Iruela-Arispe M. L. (1991)
  34. See www.sagenet.org/angio/table4.htm.
  35. Dvorak H. F., N. Engl. J. Med. 315, 1650 (1986). (10.1056/NEJM198612253152606) / N. Engl. J. Med. by Dvorak H. F. (1986)
  36. N. A. Datson J. van der Perk-de Jong
  37. van den Berg M. P., de Kloet E. R., Vreugdenhil E., Nucleic Acids Res. 27, 1300 (1999). (10.1093/nar/27.17.e17-i) / Nucleic Acids Res. by van den Berg M. P. (1999)
  38. B. Virlon et al. Proc. Natl. Acad. Sci. U.S.A. 96 15286 (1999). (10.1073/pnas.96.26.15286)
  39. V. E. Velculescu et al. Nature Genet. 23 387 (1999). (10.1038/70486)
  40. Human colon tissues were obtained <30 min after surgical removal. Normal tissue was taken from regions >10 cm away from bulk tumor tissue that had clearly defined margins. For normal tissue sheets of epithelial cells were removed with a glass slide after treatment with 5 mM dithiothreitol then 10 mM EDTA leaving an intact lamina propria for subsequent processing. After a 2-hour incubation in collagenase at 37°C cells were filtered sequentially through 400- 100- 50- and 25-μm mesh and centrifuged through a 30% preformed Percoll gradient to sediment red blood cells. Epithelial cells (Epithelial Fraction) which were found to nonspecifically bind magnetic beads were removed with Dynabeads coupled to BerEP4 (Dynal Lake Success NY). Subsequently macrophages and other leukocytes (Hematopoietic Fraction) were removed with a mixture of beads coupled to anti-CD45 anti-CD14 and anti-CD64 (Dynal). The remaining cells were stained with P1H12 antibody purified with anti-mouse immunoglobulin G (IgG)–coupled magnetic beads and lysed in mRNA lysis buffer. A detailed protocol can be obtained from www.sagenet.org/angio/protocol.htm.
  41. L. Zhang et al. Science 276 1268 (1997). (10.1126/science.276.5316.1268)
  42. Sheikh H., Yarwood H., Ashworth A., Isacke C. M., J. Cell Sci. 113, 1021 (2000). (10.1242/jcs.113.6.1021) / J. Cell Sci. by Sheikh H. (2000)
  43. We thank L. Meszler (Johns Hopkins Oncology Cell Imaging Facility) for expert help with the microscopic imaging and S. Kern and R. Hruban for pancreatic cancer samples. Supported by NIH grants CA57345 CA62924 and CGAP S98-146A. B.S.C. is a research Fellow of the National Cancer Institute of Canada supported with funds provided from the Terry Fox Run. K.W.K. received research funding from Genzyme Molecular Oncology (Genzyme). Under a licensing agreement between the Johns Hopkins University and Genzyme the SAGE technology was licensed to Genzyme for commercial purposes and V.V. B.V. and K.W.K. are entitled to a share of royalty received by the university from sales of the licensed technology. The SAGE technology is freely available to academia for research purposes. V.V. B.V. and K.W.K. are consultants to Genzyme. The university and researchers (V.V. B.V. and K.W.K.) own Genzyme stock which is subject to certain restrictions under university policy. The terms of these arrangements are being managed by the university in accordance with its conflict of interest policies.
Dates
Type When
Created 23 years, 1 month ago (July 27, 2002, 5:40 a.m.)
Deposited 1 year, 7 months ago (Jan. 13, 2024, 4:37 a.m.)
Indexed 13 hours, 42 minutes ago (Sept. 3, 2025, 6:45 a.m.)
Issued 25 years ago (Aug. 18, 2000)
Published 25 years ago (Aug. 18, 2000)
Published Print 25 years ago (Aug. 18, 2000)
Funders 0

None

@article{Croix_2000, title={Genes Expressed in Human Tumor Endothelium}, volume={289}, ISSN={1095-9203}, url={http://dx.doi.org/10.1126/science.289.5482.1197}, DOI={10.1126/science.289.5482.1197}, number={5482}, journal={Science}, publisher={American Association for the Advancement of Science (AAAS)}, author={Croix, Brad St. and Rago, Carlo and Velculescu, Victor and Traverso, Giovanni and Romans, Katharine E. and Montgomery, Elizabeth and Lal, Anita and Riggins, Gregory J. and Lengauer, Christoph and Vogelstein, Bert and Kinzler, Kenneth W.}, year={2000}, month=aug, pages={1197–1202} }